The Administration Core C will identify and accomplish administrative tasks related to the POl and facilitate the communication and dissemination of research data among the investigators. POl leadership will use Core C to facilitate the oversight ofthe research projects and cores. Core C will ensure effective and rapid communication and cooperation among investigators, projects, and cores. This core will also assist in sharing our research data with other investigators both within and outside of Memorial Sloan-Kettering Cancer Center (MSK) with a special emphasis to link Dr. Pao and the RP3 team at Vanderbilt and Dr. Sordella at the Cold Spring Harbor Laboratory with all facets of the program project through the POl intranet wiki and videoconferencing. The Administration Core C will provide: (1) administrative services;regulatory and reporting services, including preparation of annual reports and renewals;(2) budget management;(3) publication management and oversight;(4) wiki/intranet website management;(5) videoconferencing for all POl activities;(6) scheduling of POl "work-in-progress" conferences for the investigators and yearly face-toface presentations to our advisory committees;and (6) support of the oversight activities of the Executive and Scientific Advisory committees. The Administration Core C centralizes, expands, and improves the operational capabilities of all the individual research projects and cores, avoids duplication, and ensures optimum utilization of resources. The MSK Lung POl Administrator supported by this Core will meet twice monthly with the Principal Investigators and quarterly with the Executive Committee to assist them in monitoring the status of operations so that the research supported by the grant proceeds as rapidly and efficiently as possible. The MSK Lung POl Administrator, working with the Principal Investigators, will prepare and distribute a yeariy progress report for the Executive and the Internal and External Scientific Advisory Committees to assist in their annual review and oversight. The Administration Core C supports the Principal Investigators, Executive Committee, Scientific Advisory Committees, research projects and other cores;and provides services that are essential for the POl to function as an integrated research program to develop new targets for treatment for persons with lung cancers.
Lung cancers are America's leading cancer killers, responsible for 158,000 deaths this year. This grant addresses the two most critical roadblocks to improving the care and curability of persons with these illnesses: (1) understanding how cancers spread (metastasis) and (2) the lack of highly effective medicines to prevent spread or to eradicate cancers that have spread from the lung. Core C is crifical to this effort.
|Yu, Helena A; Arcila, Maria E; Harlan Fleischut, Megan et al. (2014) Germline EGFR T790M mutation found in multiple members of a familial cohort. J Thorac Oncol 9:554-8|
|Meador, Catherine B; Micheel, Christine M; Levy, Mia A et al. (2014) Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin Cancer Res 20:2264-75|
|Valiente, Manuel; Obenauf, Anna C; Jin, Xin et al. (2014) Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 156:1002-16|
|de Bruin, Elza C; Cowell, Catherine; Warne, Patricia H et al. (2014) Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov 4:606-19|
|Rekhtman, Natasha; Borsu, Laetitia; Reva, Boris et al. (2014) Unsuspected collision of synchronous lung adenocarcinomas: a potential cause of aberrant driver mutation profiles. J Thorac Oncol 9:e1-3|
|Yu, H A; Arcila, M E; Hellmann, M D et al. (2014) Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Ann Oncol 25:423-8|
|Lovly, Christine M; McDonald, Nerina T; Chen, Heidi et al. (2014) Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat Med 20:1027-34|
|Yu, Helena A; Riely, Gregory J; Lovly, Christine M (2014) Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors. Clin Cancer Res 20:5898-907|
|Pirazzoli, Valentina; Nebhan, Caroline; Song, Xiaoling et al. (2014) Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. Cell Rep 7:999-1008|
|Haq, Rizwan; Fisher, David E; Widlund, Hans R (2014) Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation. Clin Cancer Res 20:2257-63|
Showing the most recent 10 out of 59 publications